Amir Iravani

17PUBLICATIONS
76CO-AUTHORS
Predictive and prognostic markersRadiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Oncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Apr 28, 2026
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

|Mar 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.

Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci

|Feb 06, 2026
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.

Aslı D Munzur, Cameron Herberts, Edmond M Kwan

|Apr 25, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study.

Ruben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi

|Dec 23, 2023
Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis.

Anna Galligan, Roslyn Wallace, Balasubramanian Krishnamurthy

|Feb 28, 2023
FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.

Amir Iravani, Roslyn Wallace, Serigne N Lo

Pageof 3

Frequent Collaborators

4 joint publications

Michael S Hofman

4 joint publications

Shahneen Sandhu

2 joint publications

Evan Y Yu

2 joint publications

Todd Yezefski